Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Listed Wholesalers Increased Hiring of New Graduates: PJ Survey
May 17, 2004
- Annual Business Results
May 17, 2004
- Med Professionals Expect Latest Info on Quality, Efficacy, Safety from MRs: Survey
May 17, 2004
- 1st Qtr Business Results
May 17, 2004
- CPhI Japan 2004 Conference
May 17, 2004
- MEDICAL DEVICE NEWS IN BRIEF
May 17, 2004
- BUSINESS NEWS IN BRIEF
May 17, 2004
- Tie-up with Kowa Could Evolve into Full Integration: Mr Tamura of Nikken Chemicals
May 17, 2004
- BUSINESS NEWS IN BRIEF
May 17, 2004
- WEBSITE NEWS
May 17, 2004
- Korosho, Monkasho Hold Hearings on Clinical Trial Promotion Plan
May 17, 2004
- REGULATORY NEWS IN BRIEF
May 17, 2004
- WORLD NEWS IN BRIEF
May 17, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 17, 2004
- NBI, Yamanouchi Aim at Early Achievement of \40 Bil. Sales for Micardis
May 17, 2004
- WEBSITE NEWS
May 17, 2004
- Eli Lilly Japan Aims at \5 Bil. Sales with Evista in 1st Year
May 17, 2004
- Annual Business Results
May 17, 2004
- MPC New Management Determined to Take Off Toward a Global House
May 17, 2004
- 1st Qtr Business Results
May 17, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…